10-Q: McKesson Reports Strong Q2 Growth, Strategic Acquisitions Drive Performance

McKesson Corporation announced significantly increased revenues, net income, and diluted EPS for the second quarter and first half of fiscal 2026, driven by market growth and strategic acquisitions.

Summary

• Revenues for the three months ended September 30, 2025, increased by 10% to $103.15 billion, and for the six months, increased by 16% to $200.98 billion, primarily due to market growth in the North American Pharmaceutical segment and higher specialty pharmaceutical sales in Oncology & Multispecialty.
• Net income attributable to McKesson Corporation surged by 361% to $1.11 billion for the three months and by 64% to $1.89 billion for the six months ended September 30, 2025.
• Diluted earnings per common share (EPS) attributable to McKesson Corporation rose by 377% to $8.92 for the three months and by 71% to $15.16 for the six months.
• Operating income for the three months increased by 143% to $1.41 billion, and for the six months, increased by 52% to $2.44 billion.
• Total operating expenses decreased by 20% for the three months and 9% for the six months, partly due to lower remeasurement charges from the Canadian retail disposal group in the prior year.
• The company completed the acquisition of an 80% controlling interest in PRISM Vision Holdings, LLC for $871 million in cash on April 1, 2025, enhancing the Oncology & Multispecialty segment.
• A 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) was acquired for $2.5 billion in cash on June 2, 2025, also bolstering the Oncology & Multispecialty segment.
• The Board of Directors raised the quarterly dividend from $0.71 to $0.82 per common share on July 29, 2025.
• McKesson returned $1.6 billion to shareholders during the six months through $1.4 billion in common stock repurchases and $179 million in dividend payments.
• The company entered into a definitive agreement to sell its retail and distribution businesses in Norway, classifying them as held for sale, with the transaction anticipated to close after fiscal 2026.
• A provision for bad debts of $189 million was recorded for the six months ended September 30, 2025, related to the bankruptcy of customer Rite Aid Corporation.

Sentiment

Score: 8

Explanation: The company reported strong financial performance with significant increases in revenue, net income, and EPS. Strategic acquisitions are expanding key segments, and capital is being returned to shareholders through increased dividends and substantial share repurchases. While ongoing opioid litigation and a recent adverse court decision present some headwinds, the overall financial health and strategic direction are very positive.

Positives

• Revenues increased by 10% for the three months and 16% for the six months ended September 30, 2025, driven by market growth and higher specialty pharmaceutical sales.
• Net income attributable to McKesson Corporation saw substantial growth, up 361% for the three months ($1.11 billion) and 64% for the six months ($1.89 billion).
• Diluted EPS increased by 377% to $8.92 for the three months and 71% to $15.16 for the six months.
• Operating income significantly improved, rising 143% for the three months and 52% for the six months.
• Total operating expenses decreased by 20% for the three months and 9% for the six months, contributing to higher profitability.
• Strategic acquisitions of PRISM Vision Holdings, LLC ($871 million) and Core Ventures ($2.5 billion) are expanding the high-growth Oncology & Multispecialty segment.
• The company raised its quarterly dividend to $0.82 per share, demonstrating confidence in future cash flows.
• Share repurchases totaling $1.4 billion for the six months reduced weighted-average common shares outstanding, boosting EPS.
• A discrete tax benefit of $119 million was recognized due to the release of a valuation allowance in a foreign jurisdiction.

Negatives

• Gross profit margin slightly decreased by 4 basis points for the three months and 31 basis points for the six months ended September 30, 2025.
• Other income, net, decreased by 23% for the six months ended September 30, 2025, compared to the prior year, which included a $95 million net gain from equity investments.
• A provision for bad debts of $189 million was recorded for the six months ended September 30, 2025, related to the bankruptcy of Rite Aid Corporation.
• The U.S. Court of Appeals for the Fourth Circuit reversed a trial court's judgment in the Cabell County and City of Huntington opioid case, remanding it for additional proceedings.

Risks

• The company is subject to a variety of claims and legal proceedings, including ongoing opioid-related litigation, which could result in substantial payments, injunctions, or changes to business operations.
• The ultimate resolution of opioid-related litigation matters, particularly those not covered by existing settlements, remains uncertain, and the company is unable to reasonably estimate the loss or range of possible loss for these matters.
• Changes in U.S. federal regulatory posture and law may result in significant changes in healthcare policy, government funding, and other laws affecting operations, which are difficult to predict.
• Goodwill impairment testing is performed annually, and future developments such as government actions, increased regulatory uncertainty, or material changes in key market assumptions could adversely affect the fair value of reporting units.
• The sale of the Norwegian disposal group is subject to customary closing conditions, including regulatory approvals, and is not anticipated to close until after fiscal 2026, introducing potential delays or uncertainties.

Future Outlook

The company expects to continue funding short-term and long-term capital expenditures, working capital, and other cash requirements through available cash, short-term investments, and existing credit facilities. It anticipates continued quarterly cash dividends, subject to Board discretion and financial performance. Enterprise-wide restructuring initiatives are expected to be substantially complete in fiscal 2028, aiming for long-term sustainable growth. The sale of Norwegian operations is anticipated to close after fiscal 2026. The company also announced its intention to separate the Medical-Surgical Solutions segment into an independent company.

Management Comments

• "We expect our available cash generated from operations and our short-term investment portfolio, together with our existing sources of liquidity from our credit facilities, commercial paper program, and other borrowings will be sufficient to fund our short-term and long-term capital expenditures, working capital, and other cash requirements."
• "We remain adequately capitalized, including access to liquidity from our $4.0 billion revolving credit facility and $1.0 billion 364-day credit facility."
• "At September 30, 2025, we were in compliance with all debt covenants, and believe we have the ability to continue to meet our debt covenants in the future."
• "We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon our future earnings, financial condition, capital requirements, legal requirements, and other factors."
• "We believe that our future operating cash flow, financial assets, and access to capital and credit markets, including our credit facilities, give us the ability to meet our financing needs for the foreseeable future."

Industry Context

McKesson operates as a diversified healthcare services leader, navigating a highly regulated industry subject to rapid changes in policy and government funding. The company's strategic acquisitions in Oncology & Multispecialty, such as PRISM Vision and Core Ventures, reflect a broader industry trend towards consolidation and specialization in high-growth healthcare sectors like oncology and ophthalmology. The planned separation of the Medical-Surgical Solutions segment indicates a focus on streamlining operations and potentially unlocking value by allowing each entity to pursue distinct strategic paths, a common strategy in mature industries seeking to optimize portfolios. The ongoing opioid litigation continues to be a significant industry-wide challenge, with McKesson actively managing its liabilities and defenses.

Comparison to Industry Standards

• NA

Legal Proceedings

• The company is a defendant in numerous opioid-related cases, with an estimated accrued liability of $5.72 billion as of September 30, 2025, for U.S. governmental entities, Native American tribes, and certain non-governmental plaintiffs.
• Payments totaling $497 million were made during the six months ended September 30, 2025, associated with the Settlement and separate settlement agreements for opioid-related claims.
• A jury verdict in the City of Baltimore opioid case found the company liable for $192 million in compensatory damages (November 12, 2024), which was later reduced to $37 million by remittitur (June 12, 2025), with an additional $72 million ordered for monetary abatement (August 8, 2025). The company has appealed these judgments.
• The U.S. Court of Appeals for the Fourth Circuit reversed a trial court's judgment in the Cabell County and City of Huntington opioid case on October 28, 2025, remanding the case for additional proceedings.
• Four opioid-related cases are pending in Canada, with a common-issues trial scheduled to begin on February 22, 2028.
• The company reached class-action settlements with acute care hospitals (charge of $149 million in FY24, final approval April 4, 2025) and certain third-party payors (charge of $114 million in FY25, pending final approval).

Stakeholder Impact

• Shareholders benefit from increased diluted EPS, a raised quarterly dividend, and significant share repurchases, indicating strong financial returns and management confidence.
• Employees may be impacted by ongoing restructuring initiatives aimed at operational efficiencies and cost optimization, which include severance and other employee-related costs.
• Customers in the Oncology & Multispecialty segment benefit from expanded provider solutions and specialty drug distribution through recent acquisitions.
• Biopharma companies and care providers benefit from enhanced technology services and distribution capabilities offered by the Prescription Technology Solutions segment.
• Governmental entities and Native American tribes are receiving substantial payments as part of opioid litigation settlements, aimed at remediating the opioid epidemic.
• Creditors are impacted by the company's debt offerings and credit facilities, which are being used to fund strategic acquisitions and maintain liquidity, with the company reporting compliance with all debt covenants.

Next Steps

• Continue to vigorously defend against all opioid-related litigation matters not covered by settlement agreements.
• Proceed with the sale of retail and distribution businesses in Norway, anticipated to close after fiscal 2026, subject to regulatory approvals.
• Advance enterprise-wide initiatives to modernize technology, improve business continuity, compliance, and operating efficiency, with substantial completion anticipated in fiscal 2028.
• Evaluate the impact of recently issued accounting pronouncements (ASU 2024-03 and ASU 2025-06) on future disclosures.
• Continue to pay quarterly cash dividends, subject to Board discretion and financial performance.
• The Medical-Surgical Solutions segment is intended to be separated into an independent company.

Key Dates

Recommendation

McKesson Corporation demonstrates robust financial health and strategic agility, evidenced by significant year-over-year growth in revenues, net income, and diluted EPS. The company's strategic acquisitions in high-growth areas like Oncology & Multispecialty are expected to drive future expansion. Furthermore, the commitment to shareholder returns through an increased dividend and substantial share repurchase program signals strong management confidence and efficient capital allocation. While ongoing opioid litigation presents a known risk, the company has made significant provisions and is actively managing these liabilities. The announced intention to separate the Medical-Surgical Solutions segment could unlock further value by allowing each business to optimize its focus. These factors collectively position McKesson as a compelling 'strong buy' for investors seeking growth and shareholder value.

Keywords

McKesson, Healthcare Services, Pharmaceutical Distribution, Oncology, Prescription Technology, Medical-Surgical, SEC Filing, Earnings, Acquisitions, Dividends, Share Repurchase, Opioid Litigation, Financial Results, Q2 2026